Media coverage about Laboratory Corp. of America (NYSE:LH) has trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Laboratory Corp. of America earned a news impact score of 0.19 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 47.6986468435211 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s scoring:
- Laboratory Corp. of America Holdings (LH) Shares Bought by Norinchukin Bank The (americanbankingnews.com)
- Schroder Investment Management Group Has $19.34 Million Holdings in Laboratory Corp. of America Holdings (LH) (americanbankingnews.com)
- Bank of New York Mellon Corp Has $139.83 Million Position in Laboratory Corp. of America Holdings (LH) (americanbankingnews.com)
- Here's Why You Should Invest in LabCorp (LH) Stock Right Now (finance.yahoo.com)
- Here’s Why You Should Invest in LabCorp (LH) Stock Right Now (zacks.com)
A number of brokerages have recently commented on LH. Robert W. Baird set a $183.00 target price on shares of Laboratory Corp. of America and gave the company a “hold” rating in a report on Thursday, February 8th. ValuEngine cut shares of Laboratory Corp. of America from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Craig Hallum reaffirmed a “buy” rating and issued a $204.00 target price (up from $180.00) on shares of Laboratory Corp. of America in a report on Wednesday, February 7th. Citigroup upped their target price on shares of Laboratory Corp. of America from $161.00 to $184.00 and gave the company a “neutral” rating in a report on Friday, February 9th. Finally, Zacks Investment Research raised shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Six research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Laboratory Corp. of America presently has an average rating of “Buy” and an average target price of $180.73.
Laboratory Corp. of America (NYSE:LH) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $2.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.07. The firm had revenue of $2.70 billion during the quarter, compared to analysts’ expectations of $2.70 billion. Laboratory Corp. of America had a net margin of 12.15% and a return on equity of 16.30%. The firm’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.15 earnings per share. equities research analysts predict that Laboratory Corp. of America will post 11.53 earnings per share for the current year.
In other Laboratory Corp. of America news, Director Adam H. Schechter sold 1,263 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $169.29, for a total transaction of $213,813.27. Following the transaction, the director now directly owns 7,297 shares in the company, valued at $1,235,309.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Glenn A. Eisenberg sold 8,400 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $167.36, for a total transaction of $1,405,824.00. Following the transaction, the chief financial officer now owns 15,931 shares in the company, valued at $2,666,212.16. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.
Laboratory Corp. of America Company Profile
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.